Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Terns Pharmaceuticals Inc (NASDAQ: TERN) was $3.93 for the day, down -4.15% from the previous closing price of $4.10. In other words, the price has decreased by -$4.15 from its previous closing price. On the day, 0.84 million shares were traded.
Ratios:
Our analysis of TERN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 30.89 and its Current Ratio is at 30.89. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 31, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $82.
On June 22, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $16.Mizuho initiated its Buy rating on June 22, 2023, with a $16 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 01 ’25 when Kuriakose Emil sold 952 shares for $2.49 per share. The transaction valued at 2,366 led to the insider holds 53,317 shares of the business.
Jung Melita Sun bought 2,250 shares of TERN for $11,498 on Nov 30 ’24. The Chief Business Officer now owns 2,250 shares after completing the transaction at $5.11 per share. On Nov 30 ’24, another insider, Burroughs Amy L., who serves as the Chief Executive Officer of the company, bought 510 shares for $5.11 each. As a result, the insider paid 2,606 and bolstered with 19,609 shares of the company.
Stock Price History:
Over the past 52 weeks, TERN has reached a high of $11.40, while it has fallen to a 52-week low of $1.87. The 50-Day Moving Average of the stock is 32.52%, while the 200-Day Moving Average is calculated to be -25.24%.
Shares Statistics:
A total of 87.30M shares are outstanding, with a floating share count of 66.44M. Insiders hold about 23.93% of the company’s shares, while institutions hold 77.30% stake in the company.
Earnings Estimates
The current market rating for Terns Pharmaceuticals Inc (TERN) reflects the collective analysis of 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.28 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.1 and -$1.38 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$1.28, with 7.0 analysts recommending between -$0.76 and -$1.53.
